The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I study of mesothelin-targeted immunotoxin LMB-100 given as a long infusion with or without nab-paclitaxel.
 
Guillaume Joe Pegna
No Relationships to Disclose
 
Mehwish Iqra Ahmad
No Relationships to Disclose
 
Yunkai Yu
No Relationships to Disclose
 
Akira Yuno
No Relationships to Disclose
 
Min-Jung Lee
No Relationships to Disclose
 
Cody J. Peer
No Relationships to Disclose
 
Seth M. Steinberg
No Relationships to Disclose
 
Liang Cao
No Relationships to Disclose
 
Jane B Trepel
Research Funding - AstraZeneca (Inst); EpicentRX (Inst); Syndax (Inst)
 
William Douglas Figg
Research Funding - Astellas Pharma (Inst); Biocompatibles (Inst); Celgene (Inst); Nerviano Medical Sciences (Inst); NovaRX (Inst); Pfizer (Inst); TRACON Pharma (Inst)
 
Raffit Hassan
Research Funding - Aduro Biotech (Inst); Bayer (Inst); Morphotek (Inst); TCR2 Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Mesothelin domain-specific monoclonal antibodies and use thereof (Patent number:9803022)
 
Ira Pastan
No Relationships to Disclose
 
Christine Campo Alewine
No Relationships to Disclose